Literature DB >> 22371189

Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs.

Hiroshi Miyata1, Makoto Yamasaki, Yukinori Kurokawa, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND AND OBJECTIVES: There is no consensus on treatment for esophageal cancer invading adjacent organs (T4), but induction multidrug chemotherapy may be a beneficial, especially when surgery is considered as adjuvant treatment.
METHODS: We classified 169 patients with T4 esophageal cancer without distant metastasis into those undergoing chemotherapy using cisplatin and 5-FU (CF) plus adriamycin or CF plus docetaxel (79 patients) and those undergoing chemoradiotherapy using CF (90 patients). For the former group, chemoradiation was subsequently applied when surgical resection was not indicated.
RESULTS: Thirty-four patients in the chemotherapy group (43.0%) received chemoradiotherapy following chemotherapy. Although the response rate tended to be higher in the chemoradiotherapy group, there was no significant difference in the response rate between the groups (63.3% vs. 68.9%). Esophageal perforation during treatment was more frequent among the chemoradiotherapy group than the chemotherapy group (16.7% vs. 6.3%, P=0.0379). The rate of surgical resection was consequently higher for the induction chemotherapy group compared to the chemoradiotherapy group (72.1% vs. 45.6%, P=0.0005).
CONCLUSIONS: Induction triplet chemotherapy reduced esophageal perforation and increased the resectability of T4 esophageal cancers by combining second-line chemoradiotherapy. This strategy might increase the chance of curative resection for patients with T4 esophageal cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22371189     DOI: 10.1002/jso.23081

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; L Xiao; J A Roth; W L Hofstetter; G Walsh; R Komaki; Z Liao; D C Rice; A A Vaporciyan; D M Maru; J H Lee; M S Bhutani; A Eid; J C Yao; A P Phan; A Halpin; A Suzuki; T Taketa; P F Thall; S G Swisher
Journal:  Ann Oncol       Date:  2013-08-23       Impact factor: 32.976

2.  Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.

Authors:  Hideaki Shimoji; Hiroyuki Karimata; Masayoshi Nagahama; Tadashi Nishimaki
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

3.  The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Kayo Yoshida; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

Review 4.  Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2015-01-13       Impact factor: 2.549

5.  High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.

Authors:  Vanita Noronha; Amit Joshi; Sunny Jandyal; Nirmala Jambhekar; Kumar Prabhash
Journal:  Med Oncol       Date:  2014-08-23       Impact factor: 3.064

6.  New classification for the thoracic paraaortic lymph nodes of patients with esophageal squamous cell carcinoma.

Authors:  Masaaki Yamamoto; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-08-23       Impact factor: 2.549

7.  Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma?

Authors:  Keijiro Sugimura; Hiroshi Miyata; Masahiko Yano; Yoshitomo Yanagimoto; Moon Jeong Ho; Shogo Kobayashi; Hidenori Takahashi; Takeshi Omori; Masayuki Ohue; Masato Sakon
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-05

8.  Clinical Assessment of Reconstruction Involving Gastric Pull-Up Combined with Free Jejunal Graft After Total Pharyngolaryngoesophagectomy.

Authors:  Hiroshi Miyata; Keijiro Sugimura; Masaaki Motoori; Yoshiyuki Fujiwara; Takeshi Omori; Masahiro Mun; Masayuki Ohue; Masayoshi Yasui; Norikatsu Miyoshi; Takashi Fujii; Hiroki Tajima; Tomoyuki Kurita; Masahiko Yano
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

9.  Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors.

Authors:  Hideaki Shimoji; Tatsuya Kinjo; Hiroyuki Karimata; Masayoshi Nagahama; Tadashi Nishimaki
Journal:  Surg Today       Date:  2013-08-21       Impact factor: 2.549

10.  Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.

Authors:  Tomoko Katsui Taniyama; Takashi Tsuda; Kunihisa Miyakawa; Hiroyuki Arai; Ayako Doi; Mami Hirakawa; Yoshiki Horie; Takuro Mizukami; Naoki Izawa; Takashi Ogura; Yu Sunakawa; Takako Eguchi Nakajima
Journal:  Esophagus       Date:  2019-09-10       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.